Axonics (Nasdaq:AXNX) announced today that it launched its F15 recharge-free sacral neuromodulation (SNM) system in the U.S.
Irvine, California-based Axonics received FDA approval for the F15 SNM system in March.
The company designed the newly developed F15 recharge-free SNM system to feature a functional life span of over 15 years at typical stimulation parameters, with the capacity to last more than two decades at lower-energy settings.
Axonics said in a news release that the 10 cm3 size of the F15 system makes it 20% smaller than the market’s other non-rechargeable SNM device, while it has compatibility for full-body MRI with 1.5T and 3.0T whole-body scanners.
The F15 system’s proprietary algorithm recommends optimal stimulation parameters based on intraoperative responses, while its constant current automatically adjusts stimulation output. The platform features an intuitive, recharge-free key fob control with SmartMRI technology as well.
“Physician response to the Axonics F15 has been overwhelmingly positive. Our sales team is now armed with a complete portfolio of SNM products that, along with our national DTC campaign, will contribute to Axonics achieving its mission of treating more adults suffering from incontinence,” Axonics CEO Raymond W. Cohen said in the release. “We remain confident that our commitment to innovation, quality, and providing physicians and patients strong support will continue to drive SNM market expansion and advance Axonics on its path to market leadership.”